Preparation method of broad-spectrum vaccine
A vaccine and broad-spectrum technology, applied in the field of preparation of broad-spectrum vaccines, can solve problems such as the inability to present antigens, the denaturation of the original structure of viral antigens, and the instability of protein antigens
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0092] Example 1 - Generation of stable protein antigens resistant to extreme harsh conditions
[0093] Applicants have analyzed and elucidated many fundamental mechanisms of protein folding and unfolding. The disruption of hydrogen bonds was found to be the driving force for disrupting the three-dimensional structure of proteins (Wang et al., 2014). It was later found that hydrogen bonds are the main driving force for the initial folding of proteins (Lee, 2017). However, the three-dimensional structure of proteins is mostly maintained by weak hydrophobic interactions (van der Waals forces). These findings suggest that the three-dimensional structure of proteins is fragile and therefore susceptible to environmental changes that lose their original, normal structure. Small perturbations in the protein environment can lead to denaturation of the protein's three-dimensional structure. Formalin (formaldehyde), β-propiolactone (BPL), extreme pH values, certain solution component...
Embodiment 2
[0104] Example 2—Preparation of vaccines with stable antigens of influenza A strains.
[0105] Next, Applicants investigated treating influenza A virus with glutaraldehyde to produce a vaccine with stable antigens.
[0106] Specific steps are as follows:
[0107] (1), obtain H1N1 influenza virus, this H1N1 influenza virus comes from Charles River (product number: 10100374, Influenza A / PR / 8 / 34);
[0108] (2), the H1N1 influenza virus obtained in step (1) is diluted with a low-temperature buffer, and enters step (3) after its concentration is below 1.0 mg / ml;
[0109] (3), the cross-linking agent is diluted with a low-temperature buffer, and the mass concentration of the cross-linking agent is 0.005% before entering step (4);
[0110] (4), the H1N1 influenza virus dilution obtained in step (2) is diluted twice with the cross-linking agent dilution obtained in step (3), and enters step (5) after the H1N1 influenza virus concentration is 0.01mg / ml;
[0111] (5), place the patho...
Embodiment 3
[0143] Example 3—Preparation of Antigen-stabilized Type B (B) Influenza Strain Vaccines
[0144] A method similar to Example 2 was used to prepare type B (B) strain influenza vaccine. In addition, vaccines were produced using traditional methods (ie, using formaldehyde to kill viruses and prepare vaccines) as a control. Type B (B) strain virus was also obtained from Charles River (USA) company (product number: 10100379, B / Lee / 40).
[0145] Two batches of virus were prepared as follows:
[0146] Preparation of the first batch of influenza B virus vaccines - adopt the preparation method disclosed by the invention to prepare the influenza B (B) influenza strain vaccine of stable antigen, comprising the following steps:
[0147] (1), obtain the live type B (B) strain virus of purification (purchase from Charles River Company);
[0148] (2), the live virus obtained in step (1) is diluted with a low-temperature buffer, and enters step (3) after its concentration is below 1.0 mg / m...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com